PROTEXT PHARMA CEO PROVIDES SHAREHOLDERS LETTER AND DISCUSSES UPDATE ON ITS SA GOVERNMENT MEDICAL CANNABIS LICENSE ACTIVITIES
October 30 2017 - 9:35AM
InvestorsHub NewsWire
PROTEXT PHARMA CEO PROVIDES SHAREHOLDERS LETTER
AND DISCUSSES UPDATE ON ITS SA GOVERNMENT MEDICAL CANNABIS LICENSE
ACTIVITIES
FLORIDA, FL -- Oct. 30th, 2017 -- InvestorsHub
NewsWire -- Protext Pharma, Inc. (PINKSHEETS: TXTM)
("Protext" or "the Company"), a biotech company engaged in
the development of pharmaceutical botanical medicines that
are formulated with highly-bioavailable plant extracts, is pleased to provide a
shareholders update on the Company’s website. CEO Roger Baylis
Duffield discusses the company’s cannabis license initiatives and
status update including recent communications with government
officials. Link to shareholders update: http://www.protextm.co/investors/shareholder_update
Additional information has also been posted on the company’s
website regarding the company’s SA corporate lease signed earlier
this year. Link: http://www.protextm.co/investors/lease_agreement
Investors are encouraged to follow Protext using:
YouTube: http://bit.ly/ProtextYouTube
Twitter: https://twitter.com/protxtm
Instagram: https://www.instagram.com/protextm/
CONTACT INFORMATION
Info@protextm.co
Contact: (435) 881-3611
About Protext Pharma, Inc.
Protext Pharma operates two wholly owned subsidiaries; Plandai
Biotechnology South Africa (Pty) Ltd. and Cannabis Biosciences,
Inc. The Company is engaged in the research, clinical testing
and commercialization of highly bioavailable botanical
products—all-natural ingredients formulated for pharmaceutical
applications and produced under pharma-grade conditions.
Please visit http://www.protextm.co for further
information.
About Plandai Biotechnology SA
Through its wholly owned subsidiary Plandai Biotechnology SA, the
Company has the exclusive worldwide license to develop Phytofare®
extracts from live plant materials including Phytofare® catechin
complex, a highly bioavailable, and clinically proven antioxidant
complex produced from live green tea leaves.
Phytofare® can deliver a therapeutic level of catechins, which
function as powerful antioxidants, to the system where they remain
active for over 24 hours.
About Cannabis Biosciences
The Company is actively pursuing government licensing that will
allow it to use its proprietary processing and extraction
technology to commence investigations and produce a full-profile
cannabis extract, one that contains both CBD and the precursor acid
form of THC (THC-A and THC-B) found in live cannabis plant. The
Company's investigations will be designed to show that the Cannabis
Biosciences extraction process, which will use live leaf and low
temperatures to extract the phyto-chemicals, should leave the acid
forms of THC intact, resulting in a non-psychoactive extract with
full medicinal potential and having the heightened bioavailability
of other Phytofare® extracts.
Safe Harbor Statement
This release contains forward-looking statements that are based
upon current expectations or beliefs, as well as a number of
assumptions about future events. Although we believe that the
expectations reflected in the forward-looking statements and the
assumptions upon which they are based are reasonable, we can give
no assurance or guarantee that such expectations and assumptions
will prove to have been correct. Forward-looking statements are
generally identifiable by the use of words like "may," "will,"
"should," "could," "expect," "anticipate," "estimate," "believe,"
"intend," or "project" or the negative of these words or other
variations on these words or comparable terminology. The reader is
cautioned not to put undue reliance on these forward-looking
statements, as these statements are subject to numerous factors and
uncertainties, including but not limited to: adverse economic
conditions, competition, adverse federal, state and local
government regulation, international governmental regulation,
inadequate capital, inability to carry out research, development
and commercialization plans, loss or retirement of key executives
and other specific risks. To the extent that statements in this
press release are not strictly historical, including statements as
to revenue projections, business strategy, outlook, objectives,
future milestones, plans, intentions, goals, future financial
conditions, events conditioned on stockholder or other approval, or
otherwise as to future events, such statements are forward-looking,
and are made pursuant to the safe harbor provisions of the Private
Securities Litigation Reform Act of 1995. The forward-looking
statements contained in this release are subject to certain risks
and uncertainties that could cause actual results to differ
materially from the statements made. The company disclaims any
obligation to update information contained in any forward-looking
statement. This press release shall not be deemed a general
solicitation.
ProText Mobility (PK) (USOTC:TXTM)
Historical Stock Chart
From Aug 2024 to Sep 2024
ProText Mobility (PK) (USOTC:TXTM)
Historical Stock Chart
From Sep 2023 to Sep 2024